Six-transmembrane epithelial antigen of the prostate (STEAP) inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of STEAP proteins, a family of transmembrane metalloreductases. STEAP proteins, including STEAP1, STEAP2, STEAP3, and STEAP4, are involved in metal ion homeostasis, particularly in the reduction of metal ions like iron (Fe³⁺ to Fe²⁺) and copper (Cu²⁺ to Cu¹⁺). These proteins are embedded in cell membranes, with their enzymatic activity facilitating the uptake and transport of reduced metal ions essential for various cellular processes. For example, iron is critical for functions such as oxygen transport, DNA synthesis, and electron transport within mitochondria. STEAP proteins are highly expressed in epithelial tissues, including the prostate, and play important roles in regulating metal ion availability within cells. By inhibiting STEAP activity, these inhibitors disrupt the normal reduction of metal ions, leading to altered metal homeostasis.
The mechanism of action of STEAP inhibitors generally involves binding to the active site of the protein, preventing its metalloreductase activity and thereby inhibiting the reduction of iron and copper ions. Some inhibitors may directly compete with metal substrates, while others might induce conformational changes that interfere with the protein's ability to catalyze electron transfer during the reduction process. By inhibiting STEAP function, these compounds affect the cellular balance of essential metal ions, which can impact various biochemical pathways reliant on metals, such as energy production, oxidative stress regulation, and redox reactions. Research into STEAP inhibitors provides critical insights into the role of metal ion homeostasis in cellular function, and helps illuminate how dysregulation of these processes can affect broader biological systems. The study of these inhibitors deepens our understanding of the molecular mechanisms underlying metal transport and how proteins like STEAP regulate intracellular metal levels across different tissues.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Deferoxamine | 70-51-9 | sc-507390 | 5 mg | $250.00 | ||
A clinically used iron chelator, which can indirectly inhibit iron-requiring metalloreductases by reducing available iron. | ||||||
Triapine | 200933-27-3 | sc-475303 | 10 mg | $300.00 | ||
A ribonucleotide reductase inhibitor that interferes with iron metabolism, potentially affecting metalloreductase activity. | ||||||
Clioquinol | 130-26-7 | sc-201066 sc-201066A | 1 g 5 g | $44.00 $113.00 | 2 | |
A metal chelator with affinity for copper and zinc, known to inhibit metal ion-dependent enzymes. | ||||||
Ammonium tetrathiomolybdate | 15060-55-6 | sc-239242 sc-239242A sc-239242B sc-239242C | 1 g 10 g 25 g 50 g | $46.00 $199.00 $413.00 $515.00 | ||
A copper chelator, which can inhibit copper-dependent enzymes. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $47.00 | ||
A zinc ionophore that can disrupt zinc homeostasis, potentially affecting zinc-dependent metalloreductases. | ||||||
Diethyldithiocarbamic acid sodium salt trihydrate | 20624-25-3 | sc-202576 sc-202576A | 5 g 25 g | $19.00 $58.00 | 2 | |
A copper chelator that can inhibit copper-dependent enzymatic activities. | ||||||